Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2019

Open Access 01-12-2019 | Piperacillin | Letter

Increased dosing regimens of piperacillin-tazobactam are needed to avoid subtherapeutic exposure in critically ill patients with augmented renal clearance

Authors: Thibaud Besnard, Cédric Carrié, Laurent Petit, Matthieu Biais

Published in: Critical Care | Issue 1/2019

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Andersen MG, Thorsted A, Storgaard M, Kristoffersson AN, Friberg LE, Öbrink-Hansen K. Population pharmacokinetics of piperacillin in sepsis patients: should alternative dosing strategies be considered? Antimicrob Agents Chemother. 2018;62(5).
2.
Udy AA, Lipman J, Jarrett P, Klein K, Wallis SC, Patel K, Kirkpatrick CM, Kruger PS, Paterson DL, Roberts MS, Roberts JA. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? Crit Care. 2015;19:28.CrossRef
3.
Carlier M, Carrette S, Roberts JA, Stove V, Verstraete A, Hoste E, Depuydt P, Decruyenaere J, Lipman J, Wallis SC, De Waele JJ. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care. 2013;17(3):R84.CrossRef
4.
Carrié C, Legeron R, Petit L, Ollivier J, Cottenceau V, d'Houdain N, Boyer P, Lafitte M, Xuereb F, Sztark F, Breilh D, Biais M. Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion. J Crit Care. 2018;48:66–71.CrossRef
5.
Dhaese SAM, Roberts JA, Carlier M, Verstraete AG, Stove V, De Waele JJ. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients. Int J Antimicrob Agents. 2018;51(4):594–600.CrossRef
Metadata
Title
Increased dosing regimens of piperacillin-tazobactam are needed to avoid subtherapeutic exposure in critically ill patients with augmented renal clearance
Authors
Thibaud Besnard
Cédric Carrié
Laurent Petit
Matthieu Biais
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2019
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-019-2308-x

Other articles of this Issue 1/2019

Critical Care 1/2019 Go to the issue

Review

The glycocalyx: a novel diagnostic and therapeutic target in sepsis

Letter

Endocan removal during continuous renal replacement therapy: does it affect the reliability of this biomarker?

Letter

When circulatory death does not come in time in potential organ donors

Letter

Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration

Letter

Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: additional insights

Research

Subjective right ventricle assessment by echo qualified intensive care specialists: assessing agreement with objective measures